Journal Article

1α,25-dihydroxyvitamin D<sub>3</sub> inhibits prostate cancer cell invasion via modulation of selective proteases

Bo-Ying Bao, Shauh-Der Yeh and Yi-Fen Lee

in Carcinogenesis

Volume 27, issue 1, pages 32-42
Published in print January 2005 | ISSN: 0143-3334
Published online June 2005 | e-ISSN: 1460-2180 | DOI: http://dx.doi.org/10.1093/carcin/bgi170
1α,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics

GO

Show Summary Details

Preview

Inhibition of invasion and metastasis has become a new approach for treatment of advanced prostate cancer in which secondary hormone therapy has failed. Accumulating evidence indicates that 1α,25-dihydroxyvitamin D3 (1,25-VD) suppresses prostate cancer progression by inhibition of tumor growth and metastasis. However, the detailed mechanisms underlying these effects remain to be determined. Here, we used the in vitro cell invasion assay to demonstrate that 1,25-VD inhibits the invasive ability of human prostate cancer cell lines, LNCaP, PC-3 and DU 145. Three major groups of proteases, the matrix metalloproteinases (MMPs), the plasminogen activators (PAs) and the cathepsins (CPs), that are involved in tumor invasion were then examined for changes in activity and expression after 1,25-VD treatment. We found that 1,25-VD decreased MMP-9 and CPs, but not PAs activities, while it increased the activity of their counterparts, tissue inhibitors of metalloproteinase-1 (TIMP-1) and cathepsin inhibitors. Mechanistic studies showed that 1,25-VD did not suppress MMP-9 expression at the transcriptional level, but reduced its mRNA stability. In addition, 1,25-VD increased AP-1 complexes binding to TIMP-1 promoter, which contributed to the enhancement of TIMP-1 activity, and thus resulted in inhibition of MMP activity and tumor invasion. These findings support the idea that vitamin D-based therapies might be beneficial in the management of advanced prostate cancer, especially among patients who have higher MMP-9 and CPs activities.

Keywords: 1,25-VD, 1α,25-dihydroxyvitamin D3; CP, cathepsin; CPI, cathepsin inhibitor; ECM, extracellular matrix; HRPC, hormone refractory prostate cancer; MMP, matrix metalloproteinase; PA, plasminogen activator; PAI, plasminogen activator inhibitor; TIMP, tissue inhibitors of metalloproteinase; tPA, tissue PA; TPA, 12-O-tetradecanoylphorbol-13-acetate; uPA, urokinase PA

Journal Article.  7944 words.  Illustrated.

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.